Skip to main content

Branded

  • Octapharma USA to reintroduce immune disorder drug

    HOBOKEN, N.J. — The Food and Drug Administration has cleared the way for the return to market of a drug for treating immunodeficiency diseases following its recall by the manufacturer in response to patients developing internal blood clots.

  • Branded generics offer new ways to reformulate drugs

    In the classic “Arabian Nights” tale of Aladdin and his magic lamp, the evil sorcerer who made Aladdin retrieve the lamp containing the genie attempts to get it back by tricking Aladdin’s wife into giving it to him by roaming through the streets offering to trade “new lamps for old.”


  • BMS to present abstracts from Orencia studies at American College of Rheumatology meeting

    NEW YORK — Drug maker Bristol-Myers Squibb will present 20 study abstracts at the American College of Rheumatology Annual Scientific Meeting in Chicago, the company said Thursday.

    Bristol said that of those, 18 contain new data from studies of Orencia (abatacept) in patients with rheumatoid arthritis or lupus nephritis.

  • Novo Nordisk donates $50,000 to Diabetes Hands Foundation

    PRINCETON, N.J. — Novo Nordisk has donated $50,000 to an organization that raises awareness about diabetes and connects people living with it, the Danish drug maker said.

    The company said the donation, to the Diabetes Hands Foundation, was meant to recognize the Drive the Switch program, which it said had motivated more than 10,000 people to pledge to talk to loved ones and their doctors about insulin options.

  • FDA report: 35 new drugs approved in past year

    SILVER SPRING, Md. — The Food and Drug Administration has approved 35 new drugs over the past 12 months, the agency said Thursday.

  • Pfizer switch of Lipitor under consideration

    NEW YORK — It's official. Pfizer will be exploring a potential switch of its blockbuster lipid-lowering drug Lipitor (atorvastatin calcium).

  • FDA approves update to Takeda cancer drug label

    CAMBRIDGE, Mass. — The Food and Drug Administration has approved changes to the labeling of a cancer drug made by Takeda Pharmaceuticals, the drug maker said.

    Takeda and Millennium, the Japanese drug maker's cancer-drug subsidiary, announced Tuesday that the FDA approved a supplemental new drug application for the injectable multiple myeloma drug Velcade (bortezomib) that updates its label to include additional data from a clinical study showing that the drug extended patients' survival time.

  • Perrigo seeks approval for generic version of Abbott's Androgel

    ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

X
This ad will auto-close in 10 seconds